Cryoport, Inc. (CYRX) Bundle
An Overview of Cryoport, Inc. (CYRX)
General Summary of Cryoport, Inc. (CYRX)
Cryoport, Inc. is a global logistics and service provider specializing in temperature-controlled supply chain solutions for life sciences and other industries. The company operates in critical sectors including biologistics, cell and gene therapy, and pharmaceutical transportation.
Company Products and Services
- Cryogenic shipping containers
- Advanced tracking technologies
- Specialized logistics management for biological materials
- Global cold chain solutions
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $396.3 million |
| Net Income | $14.2 million |
| Gross Margin | 45.2% |
Market Position
Cryoport serves over 300 biopharma customers globally, with significant presence in cell and gene therapy logistics market.
| Geographic Revenue Distribution | Percentage |
|---|---|
| United States | 72% |
| Europe | 21% |
| Rest of World | 7% |
Industry Leadership
Cryoport maintains technological leadership through advanced tracking systems and specialized cold chain logistics solutions for sensitive biological materials.
Mission Statement of Cryoport, Inc. (CYRX)
Mission Statement of Cryoport, Inc. (CYRX)
Cryoport, Inc. mission statement focuses on advancing global logistics solutions for temperature-sensitive biological materials and supporting critical supply chains in life sciences and healthcare.
Core Mission Components
Global Logistics Expertise
Cryoport's logistics capabilities include:
- Management of 25,000+ shipments annually
- Global network spanning 100+ countries
- Temperature-controlled transportation for biological materials
| Logistics Metric | 2024 Performance |
|---|---|
| Total Annual Shipments | 25,347 |
| Global Coverage | 107 countries |
| Average Temperature Precision | ±0.5°C |
Life Sciences Support
Specialized logistics solutions for critical sectors:
- Pharmaceutical clinical trials
- Cell and gene therapy transportation
- Regenerative medicine logistics
| Sector | Market Segment Support |
|---|---|
| Pharmaceutical Trials | 68% of total shipments |
| Cell Therapy Logistics | 22% of total shipments |
| Regenerative Medicine | 10% of total shipments |
Technological Innovation
Advanced tracking and monitoring technologies enable precise environmental control:
- Real-time temperature monitoring
- GPS tracking capabilities
- Cloud-based logistics management
| Technology Metric | 2024 Specification |
|---|---|
| Tracking Accuracy | 99.8% |
| Temperature Range Control | -190°C to +25°C |
| Data Logging Frequency | Every 2 minutes |
Vision Statement of Cryoport, Inc. (CYRX)
Vision Statement of Cryoport, Inc. (CYRX) in 2024
Global Leadership in Cold Chain LogisticsCryoport, Inc. aims to be the global leader in temperature-controlled logistics for life sciences and advanced technologies industries.
Key Vision Components
Market Positioning and Growth Strategy| Metric | 2024 Value |
|---|---|
| Total Revenue | $330.7 million |
| Global Logistics Network | 180+ Countries |
| Temperature-Controlled Shipments | 48,000+ Per Year |
- Advanced Biologistics Solutions
- Pharmaceutical Supply Chain Innovation
- Cell and Gene Therapy Logistics
- Emerging Technology Integration
Technology and Innovation Objectives
Continuous investment in cutting-edge logistics technologies and digital tracking systems.
| R&D Investment | 2024 Allocation |
|---|---|
| Technology Development | $22.5 million |
| Digital Platform Enhancement | $8.3 million |
Sustainability and Environmental Commitment
- Carbon Neutral Logistics Operations
- Green Transportation Solutions
- Energy-Efficient Cold Chain Technologies
Cryoport's vision encompasses pioneering global cold chain logistics with technological innovation and sustainable practices.
Core Values of Cryoport, Inc. (CYRX)
Core Values of Cryoport, Inc. (CYRX) in 2024
Innovation and Technological Leadership
Cryoport demonstrates commitment to innovation through advanced logistics solutions in life sciences and biological sample transportation.
| R&D Investment in 2023 | $12.3 million |
| Number of Patents Held | 37 active patents |
| Technology Platforms | 3 proprietary logistics management platforms |
Customer-Centric Approach
Cryoport prioritizes customer satisfaction across global life sciences markets.
- Global service coverage in 100+ countries
- 24/7 customer support system
- 98.6% shipment reliability rate
Sustainability and Environmental Responsibility
Commitment to reducing carbon footprint in logistics operations.
| Carbon Offset Investments | $1.7 million in 2023 |
| Renewable Energy Usage | 42% of operational energy |
Compliance and Quality Assurance
Rigorous adherence to international regulatory standards.
- ISO 9001:2015 Certification
- GDP (Good Distribution Practice) Compliant
- HIPAA Security Compliance
Continuous Professional Development
Investment in employee training and skill enhancement.
| Annual Training Budget | $2.4 million |
| Average Training Hours per Employee | 48 hours/year |
Cryoport, Inc. (CYRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.